Dividend Alert: This is why Pfizer, Inc. (NYSE:PFE) will be paying investors dividends of $0.30 on Dec 1, 2016.

Dividend Alert: This is why Pfizer, Inc. (NYSE:PFE) will be paying investors dividends of $0.30 on Dec 1, 2016.

Pfizer, Inc. (NYSE:PFE) is expected to pay $0.30 on Dec 1, 2016. The indicated annual dividend is $1.20. Shareholders owning the stock before Nov 8, 2016 will be eligible to receive the payout. Based on Pfizer, Inc.’s current price of $30.00, the dividend is 1.00%. This dividend’s record date is Nov 11, 2016 and the announcement date is Sep 23, 2016. The stock increased 0.37% or $0.11 during the last trading session, hitting $30. About 300 shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 4.34% since April 5, 2016 and is downtrending. It has underperformed by 6.29% the S&P500.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $179.39 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 29.94 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.21, from 1.24 in 2016Q1. The ratio fall, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Naples Glob Advsr Limited Liability Com holds 24,327 shares or 0.35% of its portfolio. Cohen Lawrence B owns 7,353 shares or 0.15% of their US portfolio. First Merchants, a Indiana-based fund reported 63,522 shares. Auxier Asset has 85,899 shares for 0.69% of their US portfolio. Pettyjohn Wood & White Inc last reported 77,349 shares in the company. Carroll Fincl Associates holds 0.76% of its portfolio in Pfizer Inc. (NYSE:PFE) for 128,634 shares. Geneva Advsr Limited Liability Company owns 200,519 shares or 0.14% of their US portfolio. The Minnesota-based Meristem Llp has invested 0.9% in Pfizer Inc. (NYSE:PFE). Meyer Handelman owns 1.80 million shares or 2.84% of their US portfolio. Parasol Inv Lc last reported 0.33% of its portfolio in the stock. Royal Bank & Trust Of Canada has 0.36% invested in the company for 16.94M shares. California State Teachers Retirement Systems reported 13.10M shares or 0.99% of all its holdings. Dt Invest Prtnrs Limited Liability Co has invested 0.28% of its portfolio in Pfizer Inc. (NYSE:PFE). Grimes & Incorporated accumulated 54,144 shares or 0.25% of the stock. Private Advisor Grp Ltd accumulated 0.57% or 390,426 shares.

Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 2 selling transactions for $6.37 million net activity. The insider DAMELIO FRANK A sold 100,000 shares worth $3.45 million. CANGIALOSI LORETTA V also sold $2.92M worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 24. 275,000 shares with value of $9.30 million were sold by READ IAN C on Monday, May 9. 67,884 Pfizer Inc. (NYSE:PFE) shares with value of $2.29 million were sold by SUSMAN SALLY. $157,450 worth of shares were sold by OLSON LAURIE J on Wednesday, May 11. YOUNG JOHN D had sold 41,700 shares worth $1.40M on Tuesday, May 10. HILL CHARLES H also sold $1.00M worth of Pfizer Inc. (NYSE:PFE) on Monday, May 9.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, September 13 by Jefferies. The company was downgraded on Wednesday, November 2 by Argus Research. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) on Friday, August 28 with “Overweight” rating. The rating was upgraded by SunTrust on Wednesday, November 25 to “Neutral”. As per Wednesday, October 28, the company rating was maintained by S&P Research. Piper Jaffray maintained it with “Overweight” rating and $51 target price in Saturday, September 5 report. The firm has “Outperform” rating given on Tuesday, October 20 by Cowen & Co. Deutsche Bank maintained the shares of PFE in a report on Wednesday, October 28 with “Buy” rating. On Friday, October 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. Piper Jaffray maintained it with “Overweight” rating and $48 target price in Friday, August 28 report.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016, also Forbes.com with their article: “Pfizer Becomes Oversold” published on October 17, 2016, Forbes.com published: “Pfizer Divests Hospira Infusion Systems To ICU, Retaining An Interest In The …” on October 10, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Valuewalk.com and their article: “Pfizer Inc, Intercontinental Exchange Report Earnings” published on November 01, 2016 as well as Forbes.com‘s news article titled: “December 23rd Options Now Available For Pfizer (PFE)” with publication date: November 03, 2016.

PFE Company Profile

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment